21 May 2013
Keywords: corcept, corlux, misses, ph, iii, endpoint, pmd
Article | 26 March 2007
US drugmaker Corcept Therapeutics says that Study 06, the last of three Phase III trials evaluating its lead drug candidate Corlux
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 October 2006
20 May 2013
© 2013 thepharmaletter.com